About Adlai Nortye

About Adlai Nortye

Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. Our mission is to improve patient lives by developing differentiated, innovative medicines that help people live better and longer.

 We have 23 patents granted and 7 PCT published. With extensive experience in peptide and protein drugs, we have expanded our expertise into small molecules and therapeutic antibodie...

Management Team Board Of Directors Science Advisor
  • Carsten Lu, EMBA, CEO 
    ?  Founder of Adlai Nortye
    ?  Over 15 years experience of pharmaceutical R&D, manufacturing and commercialization
    ?  Bachelor of Xiamen University, EMBA of CEIBS
    ?  Responsible for strategic planning, investment and financing
  • Lars E. Birgerson, M.D., Ph.D., CDO 
    ?  Former Senior Vice President, Medical of Bristol-Myers Squibb, USA.
    ?  Physician with keen business sense and 25 years pharmaceutical industry experience in senior positions in drug development, commercial, business development and medical affairs, both globally and in the US.
    ?  Proven ability to leverage business and clinical acumen into effective solutions responsive to today’s dynamic healthcare environment.
  • XIANG YIBIN FRANK ,Ph.D., Interim CSO 
    Ph.D.of Swiss Federal Institute of Technology (ETH).

    Post-doctor of Harvard University.

    Former senior medicinal chemistry director of Sanofi Genzyme.

    ? Over 30 years of experience and success in medicinal chemistry, drug discovery and development with global pharmaceutical and biopharmaceutical companies.

    Initiated and managed multiple cross-functional programs and developed new and innovative drug therapies.
    ? Made major contributions for the identification of leading series of LTD4 antagonists, including the successful drug candidate Montelukast (Singulair).
  • YUAN RUI-RONG, M.D., President, CMO 
    ?  CMO of Eisai and BeiGene; Head of Oncology and other therapeutic Areas at Daiichi-Sankyo 
    ?  Senior Global Oncology Clinical Development Leader of Novartis
    ?  Staff Member and Attending Physician Oncology of VA NJ Health Care System, NJ Medical School
    ?  Chairman of Board Directors, Chinese American Hematologist and Oncologist Network
  • Tang Tom, M.D., MBA, SVP , Head of Development Operation 

    ?  Over  20 years experience in global clinical drug development. Completed more than 50 clinical trials.

    ?  Former chief medical officer and co-founder of Generon Inc. Former president of political affairs at Hutchison. Former head of clinical program at Pfizer.

  • Michelle Rashford, MBBS, SVP , Medical Development 
    ? Physician and leader with extensive experience in building teams within clinical development and medical affairs at a country and global level
    ? Track record in successfully leading teams to take molecules through registration and to launch
    ? Previously held senior leadership positions with BMS and Roche at local, regional and global levels
  • Dexter Fong, CFO, AICPA 
    ?  >25 years in finance/capital markets, took 3 Chinese companies public, 2 into NASDAQ and 1 into HK
    ?  Trained as an auditor and international tax consultant with various Big 4 accounting firms in HK & US
    ?  Comprehensive expertise in internal control, corporate governance, investors relations, and M&A
    ?  MBA from the University of Nevada, Reno, Masters of Accounting from the UI, Urbana Champaign
  • Carsten Lu (Chairman) 

  • Victor Yang (Director) 

  • YUAN RUI-RONG (Director) 

  • Yiming Yu (Director) 

  • Shijun Feng(Director) 

  • Yuan Tian(Director) 
  • Zhiyun Yu(Director) 
  • Gangjun Zhang(Secretary of the Board) 

  • Yufen Zhao / Academician of CAS, Professor of Xiamen University 

    · Academician of Chinese Academy of Sciences.
    · Foreign academician of the Russian Academy of International Sciences.
    · Professor of Xiamen University and Tsinghua University.

    · Founder of the "Open Laboratory of State Education Commission for the life of Organic Phosphorus Chemistry"

  • Xiaoyu Li / Professor of the University of Hong Kong 

    · Ph.D. of the University of Chicago.

    · Postdoctoral of Harvard University.

    · Professor of the University of Hong Kong.

    · Engaged in the study of life organic chemistry, chemical biology and medicinal chemistry.

    · Extensive expertise in DNA-encoded chemical libray design.

  • Junmin Quan / Professor of Peking University 

    · Ph.D. of Hong Kong University of Science and Technology.

    · Multidisciplinary background in computational chemistry, biochemistry and structural biology.

    · Extensive expertise in tumor structure biology and structure based drug design.

  • XIA WENLE / Professor of Translation Medicine, Oncology, Duke University 
    · Professor of Translation Medicine, Oncology, Duke University
    · Head of translational medicine in GSK
    · CSO of Yangtze River Pharma
    · One of inventors of EGFR/ErbB2 targeted therapies and Lapatinib
    · Responsible  for strategy of new drug R&D